Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Titel:
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Auteur:
Huang, Jing Xu, Jianming Chen, Yun Zhuang, Wu Zhang, Yiping Chen, Zhendong Chen, Jia Zhang, Helong Niu, Zuoxing Fan, Qingxia Lin, Lizhu Gu, Kangsheng Liu, Ying Ba, Yi Miao, Zhanhui Jiang, Xiaodong Zeng, Ming Chen, Jianhua Fu, Zhichao Gan, Lu Wang, Jun Zhan, Xianbao Liu, Tianshu Li, Zhiping Shen, Lin Shu, Yongqian Zhang, Tao Yang, Qing Zou, Jianjun